BACKGROUND: The risk factors responsible for an increased prevalence of obesity or overweight in survivors of acute lymphoblastic leukemia (ALL) remain controversial. We evaluated changes in body mass index (BMI) in a cohort of ALL survivors, all of whom have been followed until completion of linear growth. PROCEDURE: BMI (weight/height(2)) was used as an index of adiposity and was calculated at diagnosis, at the end of treatment, and at attainment of final height in a cohort of 126 (59 males) survivors of ALL. BMI was adjusted for age and sex by computing a BMI standard deviation score (SDS) or z score. The spectrum of therapies used included intrathecal chemotherapy given alone (n = 38) or combined with cranial irradiation (CRT; 18 Gy, n = 35; 24 Gy, n = 53) and exposure to prednisone at a low dose (<3.5 gm, n = 49), medium dose (3.5-9.4 gm, n = 46), or high dose (>9.4 gm, n = 30). RESULTS: Overall, mean +/- SEM BMI-SDS increased significantly between diagnosis (-0.18 +/- 0.08) and the end of therapy (0.41 +/- 0.09, P < 0.01), with no significant change thereafter. For patients without CRT, mean BMI-SDS remained unchanged, whereas, for those so treated, mean BMI-SDS increased significantly between diagnosis and the completion of therapy (P < 0.001). The change in mean BMI-SDS was greater in the 24 Gy group vs. the 18 Gy CRT sample (P < 0.005). In a multivariate logistic regression model, CRT was an independent predictor of being overweight (BMI >/=85 percentile) at attainment of final height [odds ratio = 1.6 (95% confidence interval 1.0-23. 1)]. The percentage of subjects who were overweight at attainment of final height was 10.5%, 40%, and 38% for subjects treated with no CRT, 18 Gy CRT, or 24 Gy CRT, respectively (P < 0.01). CONCLUSIONS: Children with ALL given CRT develop increases in their BMI-SDS early on and during treatment and remain at significant risk for becoming overweight as young adults, a development that may increase their already heightened risk for various adverse health outcomes. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND: The risk factors responsible for an increased prevalence of obesity or overweight in survivors of acute lymphoblastic leukemia (ALL) remain controversial. We evaluated changes in body mass index (BMI) in a cohort of ALL survivors, all of whom have been followed until completion of linear growth. PROCEDURE: BMI (weight/height(2)) was used as an index of adiposity and was calculated at diagnosis, at the end of treatment, and at attainment of final height in a cohort of 126 (59 males) survivors of ALL. BMI was adjusted for age and sex by computing a BMI standard deviation score (SDS) or z score. The spectrum of therapies used included intrathecal chemotherapy given alone (n = 38) or combined with cranial irradiation (CRT; 18 Gy, n = 35; 24 Gy, n = 53) and exposure to prednisone at a low dose (<3.5 gm, n = 49), medium dose (3.5-9.4 gm, n = 46), or high dose (>9.4 gm, n = 30). RESULTS: Overall, mean +/- SEM BMI-SDS increased significantly between diagnosis (-0.18 +/- 0.08) and the end of therapy (0.41 +/- 0.09, P < 0.01), with no significant change thereafter. For patients without CRT, mean BMI-SDS remained unchanged, whereas, for those so treated, mean BMI-SDS increased significantly between diagnosis and the completion of therapy (P < 0.001). The change in mean BMI-SDS was greater in the 24 Gy group vs. the 18 Gy CRT sample (P < 0.005). In a multivariate logistic regression model, CRT was an independent predictor of being overweight (BMI >/=85 percentile) at attainment of final height [odds ratio = 1.6 (95% confidence interval 1.0-23. 1)]. The percentage of subjects who were overweight at attainment of final height was 10.5%, 40%, and 38% for subjects treated with no CRT, 18 Gy CRT, or 24 Gy CRT, respectively (P < 0.01). CONCLUSIONS:Children with ALL given CRT develop increases in their BMI-SDS early on and during treatment and remain at significant risk for becoming overweight as young adults, a development that may increase their already heightened risk for various adverse health outcomes. Copyright 2000 Wiley-Liss, Inc.
Authors: Susan J Lindemulder; Linda C Stork; Bruce Bostrom; Xiaomin Lu; Meenakshi Devidas; Stephen Hunger; Joseph P Neglia; Nina S Kadan-Lottick Journal: Pediatr Blood Cancer Date: 2015-02-07 Impact factor: 3.167
Authors: James G Gurney; Janet E Donohue; Kirsten K Ness; Maura O'Leary; Stephen P Glasser; K Scott Baker Journal: Ann Epidemiol Date: 2007-07-27 Impact factor: 3.797
Authors: Lillian R Meacham; Charles A Sklar; Suwen Li; Qi Liu; Nora Gimpel; Yutaka Yasui; John A Whitton; Marilyn Stovall; Leslie L Robison; Kevin C Oeffinger Journal: Arch Intern Med Date: 2009-08-10
Authors: Jennifer A Hansen; Heather H Stancel; Lisa M Klesges; Vida L Tyc; Pamela S Hinds; Shengjie Wu; Melissa M Hudson; Lisa S Kahalley Journal: J Pediatr Oncol Nurs Date: 2014-01-22 Impact factor: 1.636
Authors: Fang Fang Zhang; Rohit P Ojha; Kevin R Krull; Todd M Gibson; Lu Lu; Jennifer Lanctot; Wassim Chemaitilly; Leslie L Robison; Melissa M Hudson Journal: J Nutr Date: 2016-10-19 Impact factor: 4.798
Authors: Jeannie S Huang; Lindsay Dillon; Laura Terrones; Lynn Schubert; William Roberts; Jerry Finklestein; Maria C Swartz; Gregory J Norman; Kevin Patrick Journal: Pediatr Blood Cancer Date: 2014-01-16 Impact factor: 3.167